David P. Southwell - 03 Aug 2026 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Reporting relationship: Director
Issuer ticker: RCKT
Reported as of: 03 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Aug 2026, 20:45:46 UTC
Prior SEC filing: 06 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Martin Wilson, as attorney-in-fact for David Southwell

Key filing fact

David P. Southwell filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 05 Aug 2026.

Key facts

This page summarizes David P. Southwell's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Aug 2026, 20:45.

Change

Previous filing in this sequence was filed on 06 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001251553 Primary reporting owner

SOUTHWELL DAVID P

Relationship: Director
Address: C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY
Signature: /s/ Martin Wilson, as attorney-in-fact for David Southwell
Signature date: 05 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCKT transaction

Common Stock

Other

Transaction value
Shares: +150,000
Change %: +275%
Price: $0.000000^*
Shares after: 204,522
Date: 03 Aug 2026
Ownership: Direct
Footnotes: F1, F2

RCKT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 113,124
Date: 03 Aug 2026
Ownership: By The David P. Southwell Irrevocable Trust Dtd 04/14/2024

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Rocket Pharmaceuticals, Inc. (the "Company") entered into a consulting agreement with the Reporting Person, dated July 21, 2026, for consulting services related to the Company's strategic and financial activities. As compensation for services rendered, the Reporting Person received 150,000 restricted stock units ("RSUs") on August 3, 2026.

Footnote F2

Represents RSUs that convert to common stock on a one-for-one basis. One-third of such RSUs will vest in full on August 3, 2027, with the remaining two-thirds vesting in equal quarterly installments over the following two years.